Sexually transmitted infections (STIs), often also referred to as sexually transmitted diseases (STDs), remain one of the most preventable and treatable global health challenges. The World Health Organization (WHO) has set an ambitious target: to eliminate key STIs—including syphilis, gonorrhea, chlamydia and trichomoniasis—as public health threats by 2030. Achieving this vision requires not only effective treatment, but also widespread access to accurate, timely and convenient diagnostics.
The STI diagnostics market is expanding quickly in response to these needs. Rising infection rates after the COVID-19 pandemic, together with greater awareness of sexual health and advances in molecular technologies, are fueling strong growth. Valued at USD 11.43 billion in 2025, the global STI diagnostics market is projected to reach USD 21.44 billion by 2034, at a compound annual growth rate (CAGR) of 7.38% between 2025 and 2034 (Precedence Research, 2024). This reflects both the scale of the challenge and the demand for more patient-centered, accessible and private testing solutions.
A variety of testing modalities are shaping this transformation. In addition to  highthroughput laboratory testing, point-of-care (POC) assays are expanding access by delivering rapid results in clinics and community settings. At the same time, at-home kits and self-collection models are gaining momentum, offering unprecedented access while meeting privacy needs that traditional testing has struggled to address. Collectively, these options are breaking down barriers, reducing stigma and supporting earlier detection and treatment—critical steps toward reducing transmission and improving public health outcomes.
As accessibility, convenience and privacy become central to diagnostics, the future of STI testing is one of greater empowerment, reach and impact. This eBook explores how innovation and shifting patient expectations are reshaping modern diagnostics—and advancing progress toward global elimination goals.
